STRENGTH

Strategic Alliances GSK and Merck.

Differentiated Product Offering Generics, Branded Gx, Branded, OTC. Broad Product portfolio imparting revenue stability. Patents. Strong presence in diverse geographies insulating business risks. Aggressive Marketing. Manufacturing Efficiencies Labour, Infrastructure and Global Quality Standards. R&D capabilities skilled scientist pool, research across Generics as well asInnovative Research (NCE, NDDS, Niche FTF), and Process Chemistry Expertise. Low cost innovation and high quality product flow. Strong CSR programs contributing to a positive reputation in the industry. Top 10 Global Generic Company with a spread over 125 countriesover 13,000 well trained Employees, over 50 nationalities. Strong presence in the International market with a major share and a strong presence in India as well. It has operations in nearly 50 countries and has 7 manufacturing plants. High investments in R&D. Well-developed industry with Strong manufacturing Base. Rich Bio-diversity.

 Non Infringing products of Active Pharmaceuticals Ingredients. High standards of purity.

WEAKNESS
It is heavily dependent upon generics for its revenue generation Constantly regulated policies by the govt means operational efficiency is affected Still lacks in few segments such as anti-malarial drugs. Lack of effective marketing strategies. It has been seen that most of the patented drugs are getting expired in between 2023-2024yrs. So the company should focus on patenting more drugs in order to survive in the market. Fragmentation of installed capacities Low technology level of Capital Goods of this section Non-availability of major intermediaries for bulk drugs Low share of India in World Pharmaceutical Production (1.2% of world production but having 16.1% of worlds population) Very low level of Biotechnology in India and also for New Drug Discovery Systems. Absence of Association between Institutes and Industry High Cost structure related to manufacturing, R&D and distribution. Low level of strategic planning for future and also for technology forecasting. Legal and Compliance issues with its manufacturing facilities at Dewas and Paonta

 Sahib in India. Tarnishing reputation in the industry because of the above two issues. Nepotism in the organization high degree of family interference and control.

OPPORTUNITY
There is a wide scope in focussing on instrumentation such as packaging kits, inhaler device and dual compartment osmotic delivery devices. The land of opportunities Africa is still unexplored due to economic calamities, the company can establish its brand value by reaching the segment and their by increasing the market share. Ageing world population can act as a fundamental growth driver by providing. Spreading attitude for soft medication (OTC drugs) Globalization Easier international trading. New markets are opening. Supply of generic drugs to developed markets. Contract manufacturing arrangements with MNCs. Niche player of global Pharmaceuticals and R&D Untapped high-growth emerging markets. Increase in demand for medicines. Possible leverage on Daiichi Sankhyos strengths. New markets are opening. Growing incomes. Growing attention for health.

 Increasing health awareness. Improvement in distribution network & brand building. They can leverage Synriam, anti-malarial drug in brand building,

THREATS Drug price control order put unrealistic ceilings on product prices and profitability and prevent a company from generating investible surplus. Increased regulations on Generic Drugs in developed countries like USA. High entry barriers technology and resource intensive. Productivity under pressure saturated developed markets. Disruptive Technologies challenging established portfolios. Unpredictable dollar rate fluctuation. Competition From MNCs High entry cost in newer markets. Non tarrifbarriers imposed by developed countries. Increasingly stringent FDA Regulations Exchange rate fluctuations Global economic slowdown Only focuses on generic market and have less patented drugs. Most of the companies have segmented Africa which is considered to be the land of opportunities. High Cost of discovering new products and fewer discoveries Non tarrif barriers imposed by developed countries